A Plasma Long Noncoding RNA Signature for Early Detection of Lung Cancer.
A Plasma Long Noncoding RNA Signature for Early Detection of Lung Cancer.
复制标题
DOI：
10.1016/j.tranon.2018.07.016
复制
发表时间：
2018-10
影响因子：
5
通讯作者：
Jiang F
中科院分区：
文献类型：
--
作者：
Lin Y;Leng Q;Zhan M;Jiang F
肺癌的早期发现是一个重大的临床挑战。长链非编码RNA（lncRNA）在肿瘤发生中具有重要作用。从原发性肿瘤或循环癌细胞直接释放的血浆lncRNA可能提供无细胞的癌症生物标志物。本研究的目的是探讨lncRNA是否可以作为早期肺癌的血浆生物标志物。通过使用液滴数字聚合酶链反应，我们确定了63名肺癌患者和33名无癌个体的发展队列以及39名肺癌患者和28名对照的验证队列的血浆中26种肺癌相关lncRNA的诊断性能。在开发队列中，26种lncRNA中的7种在血浆中被可靠地测量。两种（SNHG 1和RMRP）在肺癌患者中显示出相当高的血浆水平，与无癌对照相比（均P <0.001）。联合应用血浆lncRNA作为生物标志物诊断肺癌的敏感性为84.13%，特异性为87.88%，与肺癌的分期、组织学类型、患者的年龄和性别无关（均P > 0.05）。血浆lncRNA特征对肺癌早期检测的诊断价值在验证队列中得到证实。血浆lncRNA特征可以提供用于在早期阶段诊断肺癌的潜在的基于血液的测定。然而，一项前瞻性研究是必要的，以验证其临床价值。
The early detection of lung cancer is a major clinical challenge. Long noncoding RNAs (lncRNAs) have important functions in tumorigenesis. Plasma lncRNAs directly released from primary tumors or the circulating cancer cells might provide cell-free cancer biomarkers. The objective of this study was to investigate whether the lncRNAs could be used as plasma biomarkers for early-stage lung cancer. By using droplet digital polymerase chain reaction, we determined the diagnostic performance of 26 lung cancer–associated lncRNAs in plasma of a development cohort of 63 lung cancer patients and 33 cancer-free individuals, and a validation cohort of 39 lung cancer patients and 28 controls. In the development cohort, 7 of the 26 lncRNAs were reliably measured in plasma. Two (SNHG1 and RMRP) displayed a considerably high plasma level in lung cancer patients vs. cancer-free controls (all P < .001). Combined use of the plasma lncRNAs as a biomarker signature produced 84.13% sensitivity and 87.88% specificity for diagnosis of lung cancer, independent of stage and histological type of lung tumor, and patients' age and sex (all P > .05). The diagnostic value of the plasma lncRNA signature for lung cancer early detection was confirmed in the validation cohort. The plasma lncRNA signature may provide a potential blood-based assay for diagnosing lung cancer at the early stage. Nevertheless, a prospective study is warranted to validate its clinical value.
登录
查看更多内容
影响因子：
6.4
作者：
Gao, Lu;Ma, Jie;Jiang, Feng
通讯作者：
Jiang, Feng
影响因子：
--
作者：
Luo, Jie;Tang, Liang;Zheng, Di
通讯作者：
Zheng, Di
区分肺鳞癌和腺癌的预测模型
影响因子：
--
作者：
Li H;Jiang Z;Leng Q;Bai F;Wang J;Ding X;Li Y;Zhang X;Fang H;Yfantis HG;Xing L;Jiang F
通讯作者：
Jiang F
影响因子：
56.9
作者：
CHANG, DD;CLAYTON, DA
通讯作者：
CLAYTON, DA
影响因子：
9.4
作者：
Guthrie, J. L.;Seah, C.;Drews, S. J.
通讯作者：
Drews, S. J.